insights_auto
Per què D4S ha pujat 3,17%?
Aprofundeix méschevron_right
D4S:FRA
Daiichi Sankyo Co Ltd
16,40 €
arrow_upward
+3,17%(+0,50) 1d
9 de nov., 22:00:00 GMT+1 · EUR
search
Tots els símbols
| Símbol | Preu | Canvi | Percentatge de canvi |
|---|
insights_autoS'estan generant les estadístiques principals per a D4S...
Obre
16,00 €
Alt
16,42 €
Baix
16,00 €
Capitalització borsària
5,22 B
Volum mitjà
262,00
Volum
914,00
Alt 52 setmanes
21,56 €
Baix 52 setmanes
12,69 €
Nombre d'empleats
20 k
Obre
16,00 €
Alt
16,42 €
Baix
16,00 €
Capitalització borsària
5,22 B
Volum mitjà
262,00
Volum
914,00
Alt 52 setmanes
21,56 €
Baix 52 setmanes
12,69 €
Nombre d'empleats
20 k
Notícies
De fonts web i partners de notícies
Yahoo Finance Singapore
·
fa 1 hora
Will Cancer Drug Delivery Partnership Change Daiichi Sankyo Stock Narrative
Perfil
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.
Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development, is headquartered in Basking Ridge, New Jersey.
Daiichi Sankyo Europe, GmbH, the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.
Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations and of the International Federation of Pharmaceutical Manufacturers and Associations. Wikipedia
Sobre Daiichi Sankyo Co Ltd
Conseller delegatHiroyuki Okuzawa
Empleats20,2 k
Fundació28 de set. 2005
Seu principalChūō, Tòquio, Japó
Sector-
Sector-
Lloc webdaiichisankyo.co.jp